Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-19
    E.g., 2018-10-19



12350 items
5:26 AM, Oct 19, 2018  |  BC Extra | Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
10:38 PM, Oct 17, 2018  |  BC Extra | Financial News

PhaseBio, Osmotica price IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Wednesday. PhaseBio trading ended flat at $5 on Thursday, while...
11:23 AM, Oct 17, 2018  |  BC Extra | Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners,...
1:55 PM, Oct 16, 2018  |  BC Extra | Financial News

Taiho Ventures ups investments to $300M, to focus on oncology

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. Taiho Ventures said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical Co....
3:26 PM, Oct 12, 2018  |  BC Extra | Financial News

Biotech stocks ride tech rally

Biotech indexes ended the week on a positive note but it wasn’t enough to salvage the week. The NASDAQ Biotechnology Index (NBI), SPDR S&P Biotech ETF (XBI), BioCentury 100 and NYSE Arca Biotechnology Index (BTK) each...
1:47 PM, Oct 12, 2018  |  BC Extra | Financial News

Iovance raises $219M for Phase II trials

Iovance Biotherapeutics (NASDAQ:IOVA) raised $219.3 million in a follow-on Friday to fund five ongoing company-sponsored Phase II trials of its tumor infiltrating lymphocyte (TIL) cell therapies and prepare for potential launch of its lead TIL...
10:03 PM, Oct 10, 2018  |  BC Extra | Financial News

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million Wednesday through the sale of 5.2 million shares at $29 in a follow-on underwritten by BofA Merrill...
7:40 PM, Oct 10, 2018  |  BC Extra | Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Wednesday in the largest IPO by a biotech on NASDAQ thus far in 2018. The company...
4:40 PM, Oct 10, 2018  |  BC Extra | Financial News

Biotech slides with broader market

Biotech indexes fell Wednesday, mostly in line with the broader markets, marking significant mid-week losses. The moves come among continued trade tensions with China and follows the Federal Reserve raising interest rates for the third...
9:01 PM, Oct 09, 2018  |  BC Extra | Financial News

Versant-backed Gotham raises $54M series A

Versant Ventures unveiled a move into the RNA metabolism space with an investment in Gotham Therapeutics (New York, N.Y.). Versant co-led a $54 million series A round with Forbion Capital Partners and SR One. Gotham is...